Your browser doesn't support javascript.
loading
Flash Glucose Monitoring is Associated with HbA1c Improvement in Type 2 Diabetes Managed with Multiple Daily Injections of Insulin in the UK: A Retrospective Observational Study.
Adamson, Karen A; Gibb, Fraser W; McLaren, James; Min, Thinzar; Price, Hermione; Sankaranarayanan, Sailesh; Strzelecka, Anna.
Afiliación
  • Adamson KA; Department of Diabetes and Endocrinology, Forth Valley Royal Hospital, NHS Forth Valley, Stirling Road, Larbert, FK5 4WR, Scotland. karen.adamson@nhs.scot.
  • Gibb FW; Edinburgh Centre for Endocrinology and Diabetes, NHS Lothian, Edinburgh, Scotland.
  • McLaren J; Department of Endocrinology and Diabetes, NHS Lanarkshire, Wishaw, Scotland.
  • Min T; Diabetes Unit, Neath Port Talbot Hospital, Swansea Bay University Health Board, Port Talbot, Wales.
  • Price H; Research and Innovation Department, Southern Health NHS Foundation Trust, Southampton, England.
  • Sankaranarayanan S; Department of Endocrinology and Diabetes, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, England.
  • Strzelecka A; Warwick Medical School, University of Warwick, Warwick, England.
Diabetes Ther ; 15(9): 2109-2118, 2024 Sep.
Article en En | MEDLINE | ID: mdl-39102115
ABSTRACT

INTRODUCTION:

There is a growing body of evidence demonstrating the benefit of flash glucose monitoring in people living with type 2 diabetes mellitus (T2DM). This real-world study aimed to evaluate the effect of initiating flash glucose monitoring on change in HbA1c after 3-6 months in adults living with T2DM treated with multiple daily injections of insulin.

METHODS:

A retrospective observational study using data from ten clinical centres in the UK for adults with T2DM treated with multiple daily injections of insulin for at least 1 year was conducted. Patients who had been using the FreeStyle Libre/Libre 2 Flash Glucose Monitoring System for at least 3 months with baseline HbA1c 64-108 mmol/mol (8.0-12.0%) recorded up to 3 months prior to system use were included. Pregnant patients and those on dialysis were excluded. Patients with an HbA1c value measured 3-6 months after commencing flash glucose monitoring were included in the final analysis for evaluation of change.

RESULTS:

In total, 87 patients were included in the final analysis (mean age, 60.0 ± 11.8 years, 60.9% male, mean body mass index (BMI), 31.6 ± 5.4 [mean ± SD]). From a mean baseline HbA1c of 80 ± 11 mmol/mol (9.5% ± 1.0%), HbA1c lowered by 11 ± 14 mmol/mol (1.0% ± 1.3%) at 3-6 months (p < 0.0001). A decrease was observed independent of age, baseline HbA1c, sex, duration of insulin use and BMI subgroups.

CONCLUSIONS:

Initiation of flash glucose monitoring was associated with a clinically and statistically significant improvement in HbA1c in a real-world setting at 3-6 months.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Diabetes Ther Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Diabetes Ther Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos